National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorInstitute of Liver and Biliary Sciences, India

About this trial

Chronic liver disease is a growing health concern, with limited access to liver transplants. This study addresses the urgent need for alternatives by exploring regenerative therapies, like G-CSF, to boost the liver's natural repair. The goal is to develop safe, effective, and accessible treatments for patients who cannot undergo transplant.

Eligibility criteria

Qualifiers

Early decompensated cirrhosis patients with MELD <16

Disqualifiers

Patients with age less than 18 years or more than 65 years

Patients with Grade III ascites

CHILD C cirrhosis

Patients with a known focus of sepsis; spontaneous Bacterial Peritonitis (SBP)

Trial design

Treatments tested in this trial

  • Gcsf
  • Darbepoetin
  • Standard Medical Treatment

Treatment groups

110 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Institute of Liver and Biliary Sciences, India

Lead sponsor

Indian Council of Medical Research

Collaborator